{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:07:01Z","timestamp":1787774821385,"version":"build-2784847793"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:p>Multipurpose prevention technologies (MPTs) are multi-indication products commonly focusing on the prevention of unintended pregnancy, HIV, and\/or other sexually transmitted infections (STIs). MPTs have the potential to simplify product use and service delivery with reduced clinic visits, thus supporting improved product uptake, effective use, and cost-effectiveness. MPTs are complex products that typically include multiple active pharmaceutical ingredients (APIs), with two or more indications, and often use a device to deliver these APIs. These complexities create challenges when seeking regulatory approval. Products with previously approved APIs may be able to rely on bioequivalence (BE) studies, but still face challenges in formulation variation, drug-drug interaction, and fulfilling strict standards. MPTs that use new APIs and devices cannot rely on BE studies for approval and thus face further uncertainty, including clinical trial design for products with multiple indications and outcomes of interest. Efficacious standards of care for HIV prevention and contraception also necessitate active-control designs for registrational clinical trials, thus innovative trial designs may be needed. Compounding these challenges are special regulatory requirements for combination products, in addition to standards applied to individual API and device. Possible approval pathways for combination products exist within the US Food and Drug Administration and other global regulatory authorities, but their complexities and challenges are untested for MPTs. They are highlighted in this article to raise awareness around regulatory pathways for MPTs. In Sub-Saharan Africa, women of reproductive age are the largest percentage of new HIV infections. This, in combination with considerable rates of unintended pregnancy and rising sexually transmitted infection (STI) rates, highlights the need for products that address these complex sexual and reproductive health needs. Multipurpose prevention technologies (MPTs) commonly focus on the prevention of unintended pregnancy, HIV, and\/or other STIs in one product. MPTs combine the use of multiple pharmaceutical drugs and often a medical device to address these interrelated challenges. This creates complications in the design of studies for MPTs and in understanding the process of approval from regulatory authorities. Regulatory authorities are responsible for ensuring the safety and effectiveness of health products, and in MPTs this is complicated by targeting the prevention of multiple indications, with differing study designs and challenges, in one product. There are mechanisms in place at some regulatory authorities to evaluate MPTs, but these pathways are untested by product developers and regulatory authorities alike. Some of these pathways are highlighted below. Collaboration between diverse stakeholders like regulators, academics, product developers, and community members is necessary to build consensus on the best steps to address these challenges. MPTs are a potential tool to successfully prevent interrelated sexual and reproductive health concerns, but regulatory challenges must be addressed for safe and effective products to reach those who need them most.<\/jats:p>","DOI":"10.3389\/frph.2025.1591232","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T06:11:58Z","timestamp":1747116718000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Multipurpose prevention technologies for the prevention of unintended pregnancy, HIV, and other sexually transmitted infections: regulatory pathways and challenges"],"prefix":"10.3389","volume":"7","author":[{"given":"Logan","family":"Donaldson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alhakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Akulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thesla","family":"Palanee-Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Young Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"B1","article-title":"Global HIV & AIDS statistics \u2013 Fact sheet | UNAIDS","year":"2024"},{"key":"B2","volume-title":"Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. Accountability for the Global Health Sector Strategies 2016\u20132021: Actions for Impact","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"552028","DOI":"10.3389\/fpubh.2020.552028","article-title":"Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation","volume":"8","author":"Kombe Kombe","year":"2021","journal-title":"Front Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0220970","DOI":"10.1371\/journal.pone.0220970","article-title":"Prevalence and determinants of unintended pregnancy in sub-Saharan Africa: a multi-country analysis of demographic and health surveys","volume":"14","author":"Ameyaw","year":"2019","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1150857","DOI":"10.3389\/frph.2023.1150857","article-title":"Strategic actions to advance multipurpose prevention technologies in low- and middle-income countries","volume":"5","author":"Young Holt","year":"2023","journal-title":"Front Reprod Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/bmjsrh-2020-200662","article-title":"Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake","volume":"47","author":"Begg","year":"2021","journal-title":"BMJ Sex Reprod Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1144217","DOI":"10.3389\/frph.2023.1144217","article-title":"Cost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxis","volume":"5","author":"Milali","year":"2023","journal-title":"Front Reprod Health"},{"key":"B8","volume-title":"Multipurpose Prevention Technologies Landscape and Potential for Low-and Middle-Income Countries","author":"Young Holt","year":"2021"},{"key":"B9","volume-title":"MPT Product Development Database","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"704841","DOI":"10.3389\/frph.2021.704841","article-title":"Multipurpose prevention technologies: opportunities and challenges to ensure advancement of the most promising MPTs","volume":"3","author":"Young Holt","year":"2021","journal-title":"Front Reprod Health"},{"key":"B11","volume-title":"Principles of Premarket Pathways for Combination Products Guidance for Industry and FDA Staff","year":"2022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.tim.2015.02.006","article-title":"Multipurpose prevention technologies: the future of HIV and STI protection","volume":"23","author":"Fern\u00e1ndez-Romero","year":"2015","journal-title":"Trends Microbiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"682689","DOI":"10.3389\/frph.2021.682689","article-title":"The promise of the dual prevention pill: a framework for development and Introduction","volume":"3","author":"Friedland","year":"2021","journal-title":"Front Reprod Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1208\/s12248-012-9378-x","article-title":"Challenges and opportunities in achieving bioequivalence for fixed-dose combination products","volume":"14","author":"Mitra","year":"2012","journal-title":"AAPS J"},{"key":"B15","volume-title":"Benefit-Risk Assessment for New Drug and Biological Products Guidance for Industry","year":"2021"},{"key":"B16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40258-022-00737-w","article-title":"Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland","volume":"20","author":"Michaeli","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/biolre\/ioaa085","article-title":"Bridging the gap: advancing multipurpose prevention technologies from the lab into the hands of women\u2020","volume":"103","author":"Young Holt","year":"2020","journal-title":"Biol Reprod"},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cpt.2830","article-title":"Facilitating next-generation pre-exposure prophylaxis clinical trials using HIV recent infection assays: a consensus statement from the forum HIV prevention trial design project","volume":"114","author":"Parkin","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.contraception.2013.04.001","article-title":"The creeping pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?","volume":"88","author":"Trussell","year":"2013","journal-title":"Contraception"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e26118","DOI":"10.1002\/jia2.26118","article-title":"Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women","volume":"26","author":"Donnell","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/QAD.0000000000003494","article-title":"Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition","volume":"37","author":"Fonner","year":"2023","journal-title":"AIDS Lond Engl"},{"key":"B22","volume-title":"Contraception","year":"2023"},{"key":"B23","volume-title":"Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine\/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection (PURPOSE 1)","year":"2024"},{"key":"B24","volume-title":"MPT Target Population Identification Mapping Tool","year":"2021"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/17512433.2022.2037419","article-title":"WHO collaborative registration procedure using stringent regulatory authorities\u2019 medicine evaluation: reliance in action?","volume":"15","author":"Vaz","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/PPL-160437","article-title":"Accelerating regulatory approvals through the world health organization collaborative registration procedures","volume":"18","author":"Caturla Go\u00f1i","year":"2016","journal-title":"Pharm Policy Law"},{"key":"B27","doi-asserted-by":"publisher","first-page":"742200","DOI":"10.3389\/fmed.2021.742200","article-title":"Evaluation of the review models and approval timelines of countries participating in the southern African development community: alignment and strategies for moving forward","volume":"8","author":"Sithole","year":"2021","journal-title":"Front Med"},{"key":"B28","volume-title":"Collaborative Registration Procedure for WHO PQ-ed Medicines and its Impact on Accelerated Registration and Timely Access to Quality-assured medicines in LMICs","author":"Sillo","year":"2022"},{"key":"B29","volume-title":"WHO Expert Committee on Specifications for Pharmaceutical Preparations\u202f: Thirty-Ninth report","year":"2004"},{"key":"B30","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1177\/2168479015580384","article-title":"Partnering with patients in the development and lifecycle of medicines","volume":"49","author":"Hoos","year":"2015","journal-title":"Ther Innov Regul Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40900-022-00364-8","article-title":"Practices of patient engagement in drug development: a systematic scoping review","volume":"8","author":"Zvonareva","year":"2022","journal-title":"Res Involv Engagem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s10461-019-02715-1","article-title":"Efficacy is not everything: eliciting women\u2019s preferences for a vaginal HIV prevention product using a discrete-choice experiment","volume":"24","author":"Browne","year":"2020","journal-title":"AIDS Behav"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1002\/puh2.96","article-title":"African medicines agency: how it will change the landscape of medicines in Africa","volume":"2","author":"Ogbodum","year":"2023","journal-title":"Public Health Chall"},{"key":"B34","article-title":"The Global HIV\/AIDS pandemic: where are we now? In","volume-title":"Monday Plenary Session Presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2025","author":"Beyrer","year":"2025"}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2025.1591232\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T06:12:03Z","timestamp":1747116723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2025.1591232\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":34,"alternative-id":["10.3389\/frph.2025.1591232"],"URL":"https:\/\/doi.org\/10.3389\/frph.2025.1591232","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"article-number":"1591232"}}